These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33017894)

  • 1. Cognitive Function and Urologic Medications for Lower Urinary Tract Symptoms.
    Kim YJ; Tae BS; Bae JH
    Int Neurourol J; 2020 Sep; 24(3):231-240. PubMed ID: 33017894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Impact on cognitive function of anticholinergic drugs used for the treatment of overactive bladder in the elderly].
    Kerdraon J; Robain G; Jeandel C; Mongiat Artus P; Gamé X; Fatton B; Scheiber-Nogueira MC; Vetel JM; Mares P; Petit AC; Amarenco G;
    Prog Urol; 2014 Sep; 24(11):672-81. PubMed ID: 25214448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014).
    Oelke M; Becher K; Castro-Diaz D; Chartier-Kastler E; Kirby M; Wagg A; Wehling M
    Age Ageing; 2015 Sep; 44(5):745-55. PubMed ID: 26104505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly.
    Scheife R; Takeda M
    Clin Ther; 2005 Feb; 27(2):144-53. PubMed ID: 15811477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of anticholinergics on cognitive function in patients with neurogenic lower urinary tract dysfunction: A narrative review.
    Welk B
    Indian J Urol; 2024; 40(2):82-87. PubMed ID: 38725892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overactive bladder in the elderly: a guide to pharmacological management.
    Staskin DR
    Drugs Aging; 2005; 22(12):1013-28. PubMed ID: 16363885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trospium chloride treatment of overactive bladder.
    Biastre K; Burnakis T
    Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
    Dahm P; Brasure M; MacDonald R; Olson CM; Nelson VA; Fink HA; Rwabasonga B; Risk MC; Wilt TJ
    Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which anticholinergic drug for overactive bladder symptoms in adults.
    Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific pharmacokinetic aspects of the urinary tract.
    Korstanje C; Krauwinkel W
    Handb Exp Pharmacol; 2011; (202):267-82. PubMed ID: 21290231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.
    Gacci M; Ficarra V; Sebastianelli A; Corona G; Serni S; Shariat SF; Maggi M; Zattoni F; Carini M; Novara G
    J Sex Med; 2014 Jun; 11(6):1554-66. PubMed ID: 24708055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive and mood side effects of lower urinary tract medication.
    Muderrisoglu AE; Becher KF; Madersbacher S; Michel MC
    Expert Opin Drug Saf; 2019 Oct; 18(10):915-923. PubMed ID: 31373245
    [No Abstract]   [Full Text] [Related]  

  • 15. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Most recent findings of curative drugs for lower urinary tract symptoms in clinical practice].
    Matsukawa Y; Funahashi Y; Gotoh M
    Nihon Yakurigaku Zasshi; 2019; 154(5):265-269. PubMed ID: 31735756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
    Silva J; Silva CM; Cruz F
    Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].
    Rechberger T; Kulik-Rechberger B; Miotła P; Wróbel A
    Ginekol Pol; 2014 Mar; 85(3):214-9. PubMed ID: 24783434
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.